Abstract

Deep understanding of the genomic and immunological differences between Chinese and Western lung cancer patients is of great importance for target therapy selection and development for Chinese patients. Here we report an extensive molecular and immune profiling study of 245 Chinese patients with non-small cell lung cancer. Tumor-infiltrating lymphocyte estimated using immune cell signatures is found to be significantly higher in adenocarcinoma (ADC, 72.5%) compared with squamous cell carcinoma (SQCC, 54.4%). The correlation of genomic alterations with immune signatures reveals that low immune infiltration was associated with EGFR mutations in ADC samples, PI3K and/or WNT pathway activation in SQCC. While KRAS mutations are found to be significantly associated with T cell infiltration in ADC samples. The SQCC patients with high antigen presentation machinery and cytotoxic T cell signature scores are found to have a prolonged overall survival time.

The relationship between genomic alteration and immune context in non-small cell lung cancer (NSCLC) is complex. Here, the authors analyse the molecular and immunological landscape of 245 Chinese patients with NSCLC and find low immune infiltration correlates with genomic alterations.

Details

Title
Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients
Author
Xu-Chao, Zhang 1 ; Wang, Jun 2 ; Guo-Guang, Shao 3 ; Wang, Qun 4 ; Qu Xiaotao 5 ; Wang, Bo 5 ; Moy, Christopher 6 ; Fan, Yue 5 ; Zayed, Albertyn 7 ; Huang Xiayu 5 ; Zhang, Jingyu 5 ; Qiu, Yang 5 ; Platero Suso 6 ; Lorenzi, Matthew V 6 ; Zudaire Enrique 6 ; Yang, Jennifer 5 ; Cheng, Ying 8 ; Xu, Lin 9 ; Yi-Long, Wu 1   VIAFID ORCID Logo 

 Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou, China (GRID:grid.410643.4) 
 Peking University People’s Hospital, Beijing, China (GRID:grid.411634.5) (ISNI:0000 0004 0632 4559) 
 1st Hospital of Jilin University, Thoracic Surgery, Changchun, China (GRID:grid.64924.3d) (ISNI:0000 0004 1760 5735) 
 Zhongshan Hospital, Fudan University, Shanghai, China (GRID:grid.413087.9) (ISNI:0000 0004 1755 3939) 
 Janssen R&D China, Shanghai, China (GRID:grid.413087.9) 
 Janssen R&D, Spring House, USA (GRID:grid.413087.9) 
 Novocraft Technologies, Petaling Jaya, Malaysia (GRID:grid.413087.9) 
 Jilin Provincial Cancer Hospital, Department of Medical Oncology, Changchun, China (GRID:grid.413087.9) 
 Cancer Institute of Jiangsu Province, Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, China (GRID:grid.413087.9) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2210426735
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.